Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies.

Autor: Steuten L; Office of Health Economics, London, England, UK. Electronic address: lsteuten@ohe.org., Lothgren M; Global Value and Access, Ipsen, Zug, Switzerland., Bruce A; International Health Policy, Amgen, Sydney, Australia., Campioni M; Integrated Access Strategy Oncology, Amgen, Zug, Switzerland., Towse A; Office of Health Economics, London, England, UK.

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2024 Aug 09. Date of Electronic Publication: 2024 Aug 09.

Length of Hospital Stay and Associated Costs for Olanzapine vs. Haloperidol in the Treatment of Schizophrenia Relapse in Germany

Autor: Spannheimer, A., Reitberger, U., Clouth, J., Lothgren, M.

Publikováno v: The European Journal of Health Economics, 2003 Jan 01. 4(2), 85-89.

Externí odkaz: https://www.jstor.org/stable/3570126

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Autor: Darbà J, Kaskens L, Sorio Vilela F, Lothgren M

Publikováno v: ClinicoEconomics and Outcomes Research, Vol 2015, Iss default, Pp 105-117 (2015)

Josep Darbà,1 Lisette Kaskens,2 Francesc Sorio Vilela,3 Mickael Lothgren4 1Department of Economics, Universitat de Barcelona, 2BCN Health Economics and Outcomes Research SL, 3Amgen SA, Barcelona, Spain; 4Amgen (Europe) GmbH, Zug, Switzerland Backgro

Externí odkaz: https://doaj.org/article/b4c5108fcdfd415bb059ee93e0779611

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression.

Autor: Abduljabbar, Maram H.¹ (AUTHOR) maram.a@tu.edu.sa

Publikováno v: Pharmaceuticals (14248247). Dec2024, Vol. 17 Issue 12, p1581. 17p.